Complications from Stereotactic Body Radiotherapy for Lung Cancer
Stereotactic body radiotherapy (SBRT) has become a standard treatment option for early stage, node negative non-small cell lung cancer (NSCLC) in patients who are either medically inoperable or refuse surgical resection. SBRT has high local control rates and a favorable toxicity profile relative to...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
MDPI
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491695/ |
| id |
pubmed-4491695 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-44916952015-07-06 Complications from Stereotactic Body Radiotherapy for Lung Cancer Kang, Kylie H. Okoye, Christian C. Patel, Ravi B. Siva, Shankar Biswas, Tithi Ellis, Rodney J. Yao, Min Machtay, Mitchell Lo, Simon S. Review Stereotactic body radiotherapy (SBRT) has become a standard treatment option for early stage, node negative non-small cell lung cancer (NSCLC) in patients who are either medically inoperable or refuse surgical resection. SBRT has high local control rates and a favorable toxicity profile relative to other surgical and non-surgical approaches. Given the excellent tumor control rates and increasing utilization of SBRT, recent efforts have focused on limiting toxicity while expanding treatment to increasingly complex patients. We review toxicities from SBRT for lung cancer, including central airway, esophageal, vascular (e.g., aorta), lung parenchyma (e.g., radiation pneumonitis), and chest wall toxicities, as well as radiation-induced neuropathies (e.g., brachial plexus, vagus nerve and recurrent laryngeal nerve). We summarize patient-related, tumor-related, dosimetric characteristics of these toxicities, review published dose constraints, and propose strategies to reduce such complications. MDPI 2015-06-15 /pmc/articles/PMC4491695/ /pubmed/26083933 http://dx.doi.org/10.3390/cancers7020820 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/). |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Kang, Kylie H. Okoye, Christian C. Patel, Ravi B. Siva, Shankar Biswas, Tithi Ellis, Rodney J. Yao, Min Machtay, Mitchell Lo, Simon S. |
| spellingShingle |
Kang, Kylie H. Okoye, Christian C. Patel, Ravi B. Siva, Shankar Biswas, Tithi Ellis, Rodney J. Yao, Min Machtay, Mitchell Lo, Simon S. Complications from Stereotactic Body Radiotherapy for Lung Cancer |
| author_facet |
Kang, Kylie H. Okoye, Christian C. Patel, Ravi B. Siva, Shankar Biswas, Tithi Ellis, Rodney J. Yao, Min Machtay, Mitchell Lo, Simon S. |
| author_sort |
Kang, Kylie H. |
| title |
Complications from Stereotactic Body Radiotherapy for Lung Cancer |
| title_short |
Complications from Stereotactic Body Radiotherapy for Lung Cancer |
| title_full |
Complications from Stereotactic Body Radiotherapy for Lung Cancer |
| title_fullStr |
Complications from Stereotactic Body Radiotherapy for Lung Cancer |
| title_full_unstemmed |
Complications from Stereotactic Body Radiotherapy for Lung Cancer |
| title_sort |
complications from stereotactic body radiotherapy for lung cancer |
| description |
Stereotactic body radiotherapy (SBRT) has become a standard treatment option for early stage, node negative non-small cell lung cancer (NSCLC) in patients who are either medically inoperable or refuse surgical resection. SBRT has high local control rates and a favorable toxicity profile relative to other surgical and non-surgical approaches. Given the excellent tumor control rates and increasing utilization of SBRT, recent efforts have focused on limiting toxicity while expanding treatment to increasingly complex patients. We review toxicities from SBRT for lung cancer, including central airway, esophageal, vascular (e.g., aorta), lung parenchyma (e.g., radiation pneumonitis), and chest wall toxicities, as well as radiation-induced neuropathies (e.g., brachial plexus, vagus nerve and recurrent laryngeal nerve). We summarize patient-related, tumor-related, dosimetric characteristics of these toxicities, review published dose constraints, and propose strategies to reduce such complications. |
| publisher |
MDPI |
| publishDate |
2015 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491695/ |
| _version_ |
1613244044127764480 |